Clinical trials: Glucagon
End-stage Renal Disease
The Effect of the Incretin Hormones on the Endocrine Pancreatic Function During Hyperglycemia in End-stage Renal Disease
Patients with end-stage renal disease (ESRD) have a high prevalence of impaired glucose metabolism. The pathophysiological cause is uncertain, but disturbances in the secretion, elimination and effect of glucagon, insulin and the…
- Trial name
- NCT02237521
- Testing
- Eu- and hyperglycemic clamp, Arginine test
- Where
- Denmark
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Bo Feldt-Rasmussen
Type 2 Diabetes Mellitus
A Study of MK-0893 on Glucagon-Induced Glycemic Excursion in Healthy Male Participants Following Intravenous Administration of Glucagon, Sandostatine® and Insulin (MK-0893-002)
This is a study to assess the pharmacokinetics, safety, and tolerability of sequential single oral doses of MK-8093 10 mg, 40 mg, 200 mg, or placebo to MK-8093 (Part 1) depending on treatment assignment in young healthy male…
- Trial name
- NCT02012166
- Testing
- MK-0893 10 mg, MK-0893 40 mg, MK-0893 200 mg
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
Long-term Safety and Efficacy of Empagliflozin as Add on to GLP-1 RA
This is a multi-center, randomised, double-blind, parallel-group, safety and efficacy study of empagliflozin as add-on to GLP-1 RA in Japanese patients with Type 2 Diabetes Mellitus with insufficient glycaemic control
- Trial name
- NCT02589626
- Testing
- empagliflozin 10mg, empagliflozin 25 mg
- Where
- 16 sites in Japan
- Volunteers
- 65 people
- Sponsor
- Boehringer Ingelheim
Esophageal Neoplasms, Stomach Neoplasms
Food Intake and Gut Hormones in Patients Who Have Undergone Upper Gastrointestinal Surgery for Cancer
Improvements to treatment strategies for patients upper gastrointestinal cancers have produced an increasing population of people who remain free from disease recurrence in the long term.
- Conditions
- Esophageal Neoplasms, Stomach Neoplasms, Weight Loss, Malnutrition
- Trial name
- NCT02385617
- Testing
- Octreotide
- Where
- 2 sites in Ireland, Sweden
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- St. James's Hospital, Ireland
Pre-diabetes, Type 2 Diabetes
Effect of Exenatide, Sitagliptin or Glimepiride on Functional ß -Cell Mass
This study evaluates exenatide, sitagliptin, and glimepiride for the treatment of high blood sugar in patients with impaired fasting glucose or early type 2 diabetes.
- Trial name
- NCT00775684
- Testing
- Exenatide, Sitagliptin, Glimepiride
- Where
- 3 sites in United States
- Volunteers
- 47 people
- Sponsor
- University of Pennsylvania
Gastric Retention
Residual Gastric Content After Holding of Glucagon-like Peptide-1 Receptor Agonists Before Elective Surgery
Glucagon-like peptide-1 agonists (GLP-1RA) are a family of medications used for diabetes and weight loss. One of their effect is to slow down stomach emptying.
- Trial name
- RESIDUAL (NCT06500143)
- Testing
- Gastric ultrasound
- Where
- Canada
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Ciusss de L'Est de l'Île de Montréal
Laxity; Skin
Assess Impact of Poly-L-lactic Acid on GLP1 Subjects
Clinical trial to evaluate treatments of double-dilute poly-L-lactic acid on abdominal skin laxity in GLP1 patients versus non GLP1 patients.
- Trial name
- NCT07217743
- Testing
- Sculptra Aesthetic
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Goldman, Butterwick, Fitzpatrick and Groff
Stroke, Stroke, Acute
Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke Treated by Reperfusion Therapies
Endovascular thrombectomy (EVT) is a highly effective therapy for acute ischemic stroke with large vessel occlusion (LVO). EVT was proven efficacious in selected patients with symptoms onset or last-known-well time of up to 24…
- Conditions
- Stroke, Stroke, Acute, Stroke, Ischemic, Brain Diseases
- Trial name
- GALLOP (NCT05920889)
- Testing
- Semaglutide
- Where
- 2 sites in China, Hong Kong
- Volunteers
- 140 people
- Sponsor
- Chinese University of Hong Kong
Kidney Diseases
The Effects of Glucagon on Renal Regional Blood Flow in Humans Measured by Magnetic Resonance.
This study will investigating the effects of glucagon on renal blood flow in humans using MRI technology. Glucagon, a hormone produced by the pancreas, plays a key role in regulating blood sugar levels.
- Trial name
- NCT06872060
- Testing
- Glucagon, Glucagon+Exendin9-39, Sodium chloride
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Bispebjerg Hospital
Glucose Metabolism Disorders
The Anatomical Location, Cellular Origin and Molecular Basis of Gut-derived Glucagon Secretion
Delineation of the anatomical location, cellular origin and molecular basis of gut-derived glucagon secretion
- Trial name
- NCT03181191
- Testing
- Oral glucose tolerance test
- Where
- Denmark
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University Hospital, Gentofte, Copenhagen
glp1 Agonist, Gene Expression
Ellacor® Micro-Coring Technology® in Fitzpatrick Skin Types I-VI, Including Patients Receiving Glucagon-Like Peptide-1 Receptor Agonists
The main purpose of the study is to collect information about how the device functions in a variety of treatment areas and skin types and to find out what changes, if any, occur in the skin treated with the study device compared…
- Conditions
- glp1 Agonist, Gene Expression, Skin Laxity
- Trial name
- NCT07224880
- Testing
- ellacor
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Cytrellis Biosystems, Inc.
Idiopathic Intracranial Hypertension, Intracranial Pressure
The Effect of an Anti-obesity Drug, Semaglutide, as Treatment in New-onset Idiopathic Intracranial Hypertension (IIH) Compared to Standard Weight Management (Dietician) With Regards to Change in Weight and Intracranial Pressure
50 patients with verified new-onset Idiopathic Intracranial Hypertension are randomly allocated to standard weight management (dietician counselling) or trial intervention consisting of subcutaneous injections with Semaglutide…
- Conditions
- Idiopathic Intracranial Hypertension, Intracranial Pressure, Obesity, Pseudotumor Cerebri Syndrome
- Trial name
- IIH:DUAL (NCT06027567)
- Testing
- Semaglutide, Very Low Calorie Diet, Dietician counselling
- Where
- 2 sites in Denmark
- Volunteers
- 38 people
- Sponsor
- Rigmor Højland Jensen
Hypoglycemia, Diabetes Mellitus, Type 1
Trial to Confirm the Clinical Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Subjects With T1DM
A randomized, double-blind, parallel-group trial to confirm the clinical efficacy and safety of dasiglucagon in the rescue treatment of hypoglycemia in subjects with type 1 diabetes mellitus (T1DM) compared to placebo
- Trial name
- NCT03688711
- Testing
- Dasiglucagon
- Where
- 3 sites in United States
- Volunteers
- 45 people
- Sponsor
- Zealand Pharma
Bariatric Surgery
Incretin Hormone Antagonism After Bariatric Surgery
Using the glucagon-like peptide-1 (GLP-1) antagonist exendin(9-39) and the glucose-dependent insulinotropic peptide (GIP) antagonist GIP(3-30), the purpose of this study is to clarify the importance of endogenous GLP-1 and GIP…
- Trial name
- INCA-BAR (NCT03950245)
- Testing
- GLP-1 antagonism, GIP antagonism, GLP-1 and GIP antagonism
- Where
- 2 sites in Denmark
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Hvidovre University Hospital
Hypoglycemia
Pharmacokinetics (PK) and Pharmacodynamics (PD) of Mayne Glucagon for Injection Compared With Glucagen® (Novo Nordisk) in Healthy Volunteers
The purpose of this study is to evaluate the pharmacokinetics and pharmacodynamic bioequivalence and safety of Hospira Glucagon for Injection and GlucaGen® in healthy volunteers.
- Trial name
- NCT00745186
- Testing
- Glucagen, Mayne Glucagon
- Where
- United Kingdom
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Hospira, now a wholly owned subsidiary of Pfizer
Obesity
A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the Liver
This study is open to adults with obesity. People with a body mass index (BMI) in the range from 30 to 40 kg/m2 and a body weight of 70 to 150 kg can participate in the study.
- Trial name
- NCT05202353
- Testing
- BI 456906, Semaglutide
- Where
- Netherlands
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
Tofogliflozin GLP-1 Analogue Combination Trial
An open-label, multicenter study to evaluate 52-week long-term safety, tolerability and efficacy of Tofogliflozin with GLP-1 analogue treatment in type 2 diabetes mellitus.
- Trial name
- NCT02537834
- Testing
- Tofogliflozin, GLP-1 analogue
- Where
- 11 sites in Japan
- Volunteers
- 65 people
- Sponsor
- Kowa Company, Ltd.
Healthy Adult Participants
Effects of an Arabinoxylan-enriched Rusk on Postprandial Glucose, Insulin, Glucagon-like Peptide-1 and Appetite Responses
The aim of the present pilot randomized controlled trial is to compare the effects of the following: 1)-rusk enriched with arabinoxylans (r-rich), 2)-rusk not enriched (r-standard) on blood glucose, insulin values, glucagon like…
- Trial name
- NCT07682857
- Testing
- Enriched rusk, Standard rusk
- Where
- Italy
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of Turin, Italy
Type 2 Diabetes
GLP-1 and Microvascular Function in Type 2 Diabetes
Some gut hormones, called incretins, stimulate insulin production in order to control sugar levels but also activate brain centres and signal to stop eating.
- Trial name
- GLP-1ADDS (NCT01740921)
- Testing
- Liraglutide, diet, Aspirin
- Where
- United Kingdom
- Volunteers
- 39 people
- Sponsor
- Royal Devon and Exeter NHS Foundation Trust
Kidney Transplant Recipients
The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients
The study aims to determine the short-term efficacy, mechanisms and safety of 12 weeks of dapagliflozin and semaglutide combination therapy in 20 KTR, with and without T2D.
- Trial name
- HALLMARK (NCT05938712)
- Testing
- Dapagliflozin 10 MG, Semaglutide, 1.0 mg/mL
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- University Health Network, Toronto